The stock will cease trading and shareholders have received cash proceeds. Monitor Servier's pipeline integration for potential future value in related biotech holdings.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK AT ENTRY AT T+1- T+0 · Apr 23 $21.53entry
- T+1 · 7mo ago 0.00%α −0.78% · $21.53
- T+5 · due 7mo ago Pending
- T+20 · due 6mo ago Pending
- T+60 · due 4mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Day One Biopharmaceuticals (DAWN) was acquired by Servier Pharmaceuticals in an all-cash transaction valued at $2.5 billion, resulting in delisting from Nasdaq and termination of all existing equity plans. The merger closed after Servier secured 85.34% of shares in a tender offer.
Key Facts
- Servier Pharmaceuticals completed acquisition of Day One Biopharmaceuticals for $2.5 billion in equity value
- All outstanding shares converted to $21.50 in cash per share
- Company delisted from Nasdaq following merger completion
- Board and officers replaced with Servier appointees
- All equity incentive plans terminated
Financial Impact
Total equity value of $2.5 billion paid in cash to shareholders
Risk Factors
- Loss of public market liquidity for former DAWN shareholders
- Integration risk of Day One's pipeline into Servier's portfolio
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-171997 |
| Document: d27888dex32.htm | 0001193125-26-171997 |
| Document: d27888dex31.htm | 0001193125-26-171997 |
| Document: 0001193125-26-171997-index-headers.html | 0001193125-26-171997 |
| Document: 0001193125-26-171997-index.html | 0001193125-26-171997 |
| Document: 0001193125-26-171997.txt | 0001193125-26-171997 |
Track record
6 reports on DAWN
The track record builds as more bullish or bearish reports settle.
Filters
- May 4, 202628w ago 15-12G Neutral 5/10 No price data
- Apr 23, 202629w ago 25-NSE Neutral 9/10 Entry $21.53 No price data
- Apr 23, 202629w ago 8-K Neutral 9/10 Viewing Entry $21.53 No price data
- Apr 17, 202630w ago 10-K/A Neutral 4/10 Entry $21.48 No price data
- Mar 6, 202636w ago Press Release Bullish 9/10 Entry $21.20 to $21.46 ▲ +1.23% +3.27% vs SPY
- Feb 24, 202637w ago 8-K Bullish 8/10 Entry $10.92 to $21.37 ▲ +95.79% +101.02% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers